Inflammatory Bowel Diseases最新文献

{"title":"Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: Supporting the Clinician's Role in Disease Interpretation.","authors":"Seak Hee Oh, Chathruckan Rajendra","doi":"10.1093/ibd/izaf165","DOIUrl":"https://doi.org/10.1093/ibd/izaf165","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Severity of Rectal Inflammation and Pouch Surgery Outcome in Patients with Ulcerative Colitis: A Retrospective Cohort Study.","authors":"Frederik Rud Windfeldt Bækgaard, Mie Dilling Kjær, Sören Möller, Stine Wikkelsøe Hovvang, Jens Kjeldsen, Rannveig Dora Baldursdottir, Sara Mehinovic, Sally Adham Al-Yousefy, Jakob Ravn Grimm, Mark Bremholm Ellebæk","doi":"10.1093/ibd/izaf194","DOIUrl":"https://doi.org/10.1093/ibd/izaf194","url":null,"abstract":"<p><strong>Background: </strong>Pouch failure after ulcerative colitis (UC) necessitates either pouch excision or establishment of a permanent diverting stoma. The aim of this study was to explore if rectal inflammation prior to pouch creation affected the risk of developing pouch failure.</p><p><strong>Methods: </strong>Patients 18 years and older with ulcerative colitis undergoing J-pouch surgery at Odense University Hospital between 1983 and 2020 were included. Pouch failure was defined as either the presence of ileostomy more than 1 year after ileo pouch-anal anastomosis (IPAA) or pouch removal. Rectal inflammation was defined by 3 measures: using the Nancy index on pathology examination of the resected rectum, endoscopically using latest Mayo score from the year preceding the IPAA, and as active anti-inflammatory treatment four weeks prior to IPAA.</p><p><strong>Results: </strong>A total of 434 patients met the inclusion criteria, with 66 patients (15%) experiencing pouch failure with mean time of 5.63 years. Acute inflammation (Nancy grade 2-4) was observed in 70% of the patients. Active anti-inflammatory treatment was observed in 37% of patients, and 67% had undergone endoscopy within 1 year prior to IPAA. No significant association was found between the Nancy Index Grade and pouch failure, time to pouch failure, postoperative complications, or long-term pouch complications. Furthermore, neither the Mayo score grade nor active medical UC therapy predicted the risk of pouch failure.</p><p><strong>Conclusion: </strong>Rectal inflammation prior to IPAA does not increase risk of pouch failure, postoperative complications, or long term pouch dysfunction.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Unaddressed Dimensions in Long-Term Regenerative Therapy for Perianal Crohn's Fistulas.","authors":"Ting Xue, Youzhen Pan, Libo Zhou","doi":"10.1093/ibd/izaf208","DOIUrl":"10.1093/ibd/izaf208","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review\".","authors":"Prajnasini Satapathy, Rachana Mehta, Ranjana Sah","doi":"10.1093/ibd/izaf211","DOIUrl":"https://doi.org/10.1093/ibd/izaf211","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study.","authors":"Spencer Frost, Chetan Ambastha, Devin Patel, Andrew Roney, Alexandra Greb, Maricela Rangel-Garcia, Jenny S Sauk, Christopher Chang, Sunhee Park, Alyssa Parian, Andrew Suchan, Eric Moughames, Mahesh Krishna, Reezwana Chowdhury, Sowmya Sharma, Laura Maas, Andrew Ho, Mark Lazarev, Berkeley N Limketkai, David Limsui, Kian Keyashian","doi":"10.1093/ibd/izaf170","DOIUrl":"https://doi.org/10.1093/ibd/izaf170","url":null,"abstract":"<p><strong>Background: </strong>It has been theorized that age related immunosenescence reduces the risk of developing anti-drug antibodies (ADAs). This has significant implications regarding choice of therapy and need for routine drug monitoring in this group. We investigated the incidence of ADAs in older adults compared to younger adults with inflammatory bowel disease (IBD).</p><p><strong>Methods: </strong>We conducted a multicenter retrospective cohort study including all older adults (ages ≥60 years) with IBD treated with a tumor necrosis factor inhibitors (TNFi); adults ages 18-59 years old were included in a 4:1 ratio. Kaplan-Meier and Cox regression methods compared longitudinal risk of ADA development between groups. Multivariable models evaluated the association of potential risk factors with ADA development.</p><p><strong>Results: </strong>182 (19.7%) older adults and 738 (80.2%) younger adults were included in the study. The risk of ADAs was higher in older adults compared to younger adults (adjusted hazard ratio [aHR] 2.20; 95% confidence interval [CI] 1.44-3.36). Proactive therapeutic drug monitoring (TDM) was inversely associated with ADA development (aHR 0.36; 95% CI 0.25-0.52).</p><p><strong>Conclusion: </strong>Older adults are more likely to develop ADAs against TNFi compared to younger adults. Proactive TDM may be considered in this population for early identification of ADAs and subtherapeutic trough levels, enabling timely dose escalation or treatment modification.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.","authors":"Vipul Jairath, Shashi Adsul, Mariangela Allocca, Silvio Danese, Marla C Dubinsky, Marcelo Freire de Oliveira, Christopher Ma, Torsten Kucharzik, Kerri L Novak, Remo Panaccione, Itzel Romo Bautista, Bruce E Sands, Stuart A Taylor, Rune Wilkens, Christian Maaser","doi":"10.1093/ibd/izaf196","DOIUrl":"https://doi.org/10.1093/ibd/izaf196","url":null,"abstract":"<p><p>This narrative review summarizes the current knowledge on using intestinal ultrasonography (IUS) to evaluate disease activity in patients with Crohn's disease (CD) and explores its potential role in clinical trials. Current trial endpoints and their limitations are discussed, highlighting the need for more patient-centric approaches, including increased use of magnetic resonance enterography (MRE) and IUS. Intestinal ultrasonography offers several advantages: it is noninvasive, requires no sedation, bowel preparation, or exposure to ionizing radiation, and enables real-time assessment of disease activity. It also demonstrates high sensitivity and specificity for detecting transmural inflammation and complications such as strictures, abscesses, and fistulas. Compared with cross-sectional imaging modalities like MRE and computed tomography, IUS is more patient-friendly, cost-effective, and suitable for point-of-care examination. However, challenges remain, including the lack of a universally accepted disease activity scoring system for MRE or IUS, despite the development and validation of several scoring tools. Key unmet needs include standardization of image acquisition and reporting, adequate training of healthcare professionals, improved access to equipment, and reimbursement pathways. Intestinal ultrasonography is increasingly being integrated into clinical trials to assess transmural inflammatory changes in CD, with IUS-based measures of transmural remission or response showing promise as potential endpoints. Although its advantages are clear, addressing these unmet needs is essential to broaden the adoption of IUS in both clinical trials and routine clinical practice.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.","authors":"Stefan Schreiber, Scott D Lee, C Janneke van der Woude, Ignacio Marín-Jiménez, Douglas C Wolf, Elisabeth Schnoy, Bruce Salzberg, Christopher Busse, Maciej Nazar, Tony Ma, Stephan Borghorst, Christopher Gasink, Thomas Baker, Bridget Godwin, Omoniyi J Adedokun, Brian G Feagan","doi":"10.1093/ibd/izaf163","DOIUrl":"https://doi.org/10.1093/ibd/izaf163","url":null,"abstract":"<p><strong>Background: </strong>The POWER study (NCT03782376) evaluated efficacy and safety of a single ustekinumab intravenous (IV) reinduction dose versus placebo under continued ustekinumab subcutaneous (SC) treatment in adult patients with moderately to severely active Crohn's disease who demonstrated a secondary loss of response to ustekinumab every 8 weeks (q8w) maintenance therapy.</p><p><strong>Methods: </strong>Patients were randomly assigned 1:1 at Week 0 to ustekinumab IV reinduction (ustekinumab ∼6 mg/kg and SC placebo) or continuous maintenance (IV placebo and SC ustekinumab 90 mg q8w). Clinical and biomarker assessments occurred at Weeks 0, 8, 16, and 24 with optional ileocolonoscopy at Weeks 0 and16. The primary endpoint was clinical response (≥100-point decrease from baseline Crohn's Disease Activity Index [CDAI] score or CDAI <150) at Week 16. Safety events were analyzed through Week 36 and serum samples were collected for pharmacokinetic analyses and anti-ustekinumab antibody detection.</p><p><strong>Results: </strong>Overall, 215 patients were randomized: 108 to the IV reinduction group and 107 to the SC group. In the IV reinduction group, 49.1% achieved clinical response at Week 16 versus 37.4% in the SC group (adjusted treatment difference 11.5% [95% CI: -1.5%, 24.5%; P = .089]). Proportions of patients with endoscopic remission and improvement, normalization of inflammatory biomarkers, and improvement in IBDQ score were greater in the IV reinduction group vs the SC group. No new safety signals were identified.</p><p><strong>Conclusions: </strong>Although the primary endpoint of clinical response was not met at Week 16, ustekinumab IV reinduction showed numerical improvements in objective endpoints including inflammatory biomarkers and endoscopic outcomes compared with SC maintenance therapy. Safety and immunogenicity results were consistent with the established profile of ustekinumab.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking Safety Assessment of Rotavirus Vaccination in Biologic-Exposed Infants: Methodological Nuances Matter.","authors":"Jinyu Wu, Shiquan Yu","doi":"10.1093/ibd/izaf201","DOIUrl":"https://doi.org/10.1093/ibd/izaf201","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Retrotransposon Transcriptome in Pediatric Crohn's Disease.","authors":"Qing Chen, Colton McNinch, Eve May, Phoebe LaPoint, Galina Koroleva, Ashleigh Sutton, Ruhika Prasad, Diana Jo, Brynn O'Laughlin, Anal Patel, Shira Levy, Suchitra K Hourigan","doi":"10.1093/ibd/izaf190","DOIUrl":"10.1093/ibd/izaf190","url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease (CD) is an autoimmune condition with inflammation of the gastrointestinal tract. The etiology of CD is complex with underlying mechanisms only partially elucidated. Retrotransposons, a category of transposable elements within a genome, have been shown to contribute to the pathogenesis of inflammatory and autoimmune disorders. This research aimed to explore the expression of retrotransposons in children with CD.</p><p><strong>Methods: </strong>To assess the expression level of retrotransposons, high-throughput expression analysis at the locus level was performed including LINE, SINE, and LTR-retrotransposons (human endogenous retroviruses (HERVs)) in total RNAseq of ileal and rectal biopsies from treatment-naïve children with CD and age-matched non-Inflammatory Bowel Disease (IBD) controls (CMU-dataset). Findings were validated in public datasets (GSE57945 Ileal; GSE117993 Rectal) from the pediatric RISK study.</p><p><strong>Results: </strong>Consistent separation of retrotransposon expression between CD and non-IBD controls in both the CMU-dataset and the RISK-dataset was observed in ileal biopsies, but less so in rectal biopsies. In total, 118 differentially expressed retrotransposon loci were identified (27 upregulated and 91 downregulated; 74 LINE-1 and 44 HERV) in CMU-ileal dataset. Fifteen retrotransposon loci were consistently downregulated in both datasets (CMU-ileal and GSE57945): HERV9N-int, HERV9-int (2 loci), HERVH-int (2 loci), HERVK22-int, LTR5A, HERVK-int, L1PA4 (5 loci), L1PA6, L1PA14.</p><p><strong>Conclusions: </strong>Retrotransposon transcriptome in children with CD significantly differed from non-IBD controls in ileal biopsies with 15 retrotransposon loci consistently downregulated in CD. The possible regulatory function of these retrotransposon loci merits additional research. This study may provide valuable perspectives for the advancement of novel therapeutic strategies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naïve de Novo Pediatric Inflammatory Bowel Disease.","authors":"Eva Vermeer, Femke M Prins, Iwan J Hidding, Jasmijn Z Jagt, Robert de Jonge, Marc A Benninga, Ranko Gacesa, Rinse K Weersma, Nanne K H de Boer, Tim G J de Meij","doi":"10.1093/ibd/izaf184","DOIUrl":"https://doi.org/10.1093/ibd/izaf184","url":null,"abstract":"<p><strong>Background and aims: </strong>Microbiome studies reveal distinct microbial differences in inflammatory bowel disease (IBD), indicating its potential role in pathophysiology and as a noninvasive diagnostic biomarker. This study aims to profile the gut microbiome in children with IBD, compared to both healthy controls (HC) and controls with gastrointestinal symptoms (CGI), and to assess the potential of microbiome profiles as noninvasive diagnostic markers for de novo treatment-naïve pediatric IBD, and as early predictive markers for therapy response.</p><p><strong>Methods: </strong>We analyzed baseline fecal samples and clinical data from 103 therapy-naïve children with IBD, 75 CGI, and 356 age and sex matched HC. Metagenomic sequencing was performed, and prediction models assessed diagnostic potential and prediction of induction therapy response at 3 months.</p><p><strong>Results: </strong>Alpha diversity progressively decreased from HC to CGI (P < .001) and decreased even further in IBD patients (P = .0056). Beta diversity analysis showed significant clustering differences (P < .001, R2 = 0.045). Differential abundance analysis revealed 116 species differing between HC and IBD, and 30 species between CGI and IBD. Prediction models based on microbiome features accurately distinguished IBD from HC (area under the curve [AUC] = 0.96) and from CGI (AUC = 0.71). However, these models were outperformed by clinical features, such as fecal calprotectin. Microbiome-based prediction of response to induction therapy in general showed limited accuracy (AUC = 0.63), as well as for response to nutritional induction therapy (AUC = 0.67).</p><p><strong>Conclusions: </strong>We observed profound gut microbiome differences between de novo, therapy-naïve pediatric IBD patients and controls. While microbiome profiles hold promise for improving diagnostic precision, their predictive value for therapy response seems limited.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}